By weaponising the body’s own immune defences, these drugs have shown great promise in clinical trials and are now experiencing significant commercial success. As cancer affects the efficient function of the immune system by disrupting the careful balance between immune repression/tolerance and stimulation, current immunotherapies powerfully work to restore this balance. However, the downside is that this can potentially lead to serious side-effects such as inflammatory disorders and autoimmune diseases. Using autoantibodies as biomarkers could help to minimise these issues by making it easier to predict patient responses and select suitable patients for each therapy, as well as by offering a tool for detecting immunerelated Adverse Events (irAEs) as early as possible and ideally before clinical symptoms occur.....

You just need to REGISTER - its FREE - to read the rest of this article straight away.